Target Name: MIR153-1
NCBI ID: G406944
Review Report on MIR153-1 Target / Biomarker Content of Review Report on MIR153-1 Target / Biomarker
MIR153-1
Other Name(s): hsa-miR-153-3p | MIRN153-1 | MicroRNA 153-1 | microRNA 153-1 | mir-153-1 | hsa-mir-153-1

MIR153-1: A Potential Cancer Drug Target and Biomarker

MIR153-1 (hsa-miR-153-3p) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer. Its unique structure and function have made it an attractive target for researchers to study, and its potential as a drug has led to a great deal of interest and discussion in the scientific community.

MIR153-1 is a microRNA (miRNA), a small non-coding RNA molecule that plays a crucial role in post-transcriptional gene regulation. It is typically expressed in high levels in various tissues and cells and has been shown to play a role in the regulation of cell proliferation, apoptosis, and other cellular processes.

One of the key features of MIR153-1 is its unique structure. It is a single-stranded RNA molecule that has 19 amino acid residues and a calculated molecular weight of 20.7 kDa. Its unique structure allows it to interact with various cellular components and molecules, making it a promising target for drugs that can modulate its activity.

MIR153-1 has been shown to play a role in the regulation of cell apoptosis, which is the process by which cells undergo programmed cell death. It has been shown to induce apoptosis in various cell types, including cancer cells, and to play a role in the regulation of cell cycle progression.

In addition to its role in apoptosis, MIR153-1 has also been shown to play a role in cell proliferation. It has been shown to promote the growth and proliferation of various cell types, including cancer cells, and to play a role in the regulation of cell proliferation.

MIR153-1 has also been shown to have a negative impact on cancer cell survival. It has been shown to inhibit the survival of various cancer cell lines in cell culture and to promote the growth of cell lines that are resistant to its effects.

These findings suggest that MIR153-1 may be an attractive drug target for cancer treatment. By modulating its activity, researchers may be able to inhibit the growth and survival of cancer cells and to promote the development of new, more effective cancer treatments.

In addition to its potential as a cancer drug, MIR153-1 has also been shown to have potential as a biomarker. Its unique structure and function make it an attractive target for diagnostic tests, such as qRT-PCR, RNA sequencing, and mass spectrometry. These tests have the potential to diagnose various diseases, including cancer, based on the expression levels of MIR153-1 in cells or tissues.

MIR153-1 has also been shown to have potential as a therapeutic target for other diseases. Its unique structure and function make it an attractive target for drugs that can modulate its activity. For example, researchers have shown that MIR153-1 can be inhibited by small molecules, such as inhibitors of RNA binding proteins, and that this can lead to the inhibition of its activity.

In conclusion, MIR153-1 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer. Its unique structure and function make it an attractive target for researchers to study, and its potential as a drug or biomarker has led to a great deal of interest and discussion in the scientific community. Further research is needed to fully understand its role in disease and to develop new treatments based on its unique properties.

Protein Name: MicroRNA 153-1

The "MIR153-1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR153-1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MIR153-2 | MIR1537 | MIR1538 | MIR1539 | MIR154 | MIR155 | MIR155HG | MIR1587 | MIR15A | MIR15B | MIR16-1 | MIR16-2 | MIR17 | MIR17HG | MIR181A1 | MIR181A1HG | MIR181A2 | MIR181A2HG | MIR181B1 | MIR181B2 | MIR181C | MIR181D | MIR182 | MIR1825 | MIR1827 | MIR183 | MIR184 | MIR185 | MIR186 | MIR187 | MIR188 | MIR18A | MIR18B | MIR1908 | MIR1909 | MIR190A | MIR190B | MIR191 | MIR1910 | MIR1911 | MIR1912 | MIR1913 | MIR1914 | MIR1915 | MIR1915HG | MIR192 | MIR193A | MIR193B | MIR193BHG | MIR194-1 | MIR194-2 | MIR194-2HG | MIR195 | MIR196A1 | MIR196A2 | MIR196B | MIR197 | MIR1972-1 | MIR1972-2 | MIR1973 | MIR1976 | MIR198 | MIR199A1 | MIR199A2 | MIR199B | MIR19A | MIR19B1 | MIR19B2 | MIR200A | MIR200B | MIR200C | MIR200CHG | MIR202 | MIR202HG | MIR203A | MIR203B | MIR204 | MIR205 | MIR2052 | MIR2052HG | MIR2053 | MIR2054 | MIR205HG | MIR206 | MIR208A | MIR208B | MIR20A | MIR20B | MIR21 | MIR210 | MIR210HG | MIR211 | MIR2110 | MIR2113 | MIR2114 | MIR2115 | MIR2116 | MIR2117 | MIR212 | MIR214